As part of the NET4CGD dissemination strategy and in order to provide information to patients, a Q&A titled "New gene therapy trial for X-CGD" has been created that can be found on the NET4CGD website under the "NET4CGD Project" tab.
As the European Commission's primary public repository and portal to disseminate information on all EU-funded research projects and their results in the broadest sense, CORDIS has published a summary on the NET4CGD project. This project summary is available in several languages (French, English, German, Spanish, Italian and Polish) that can be found on the NET4CGD website under the "NET4CGD Project" tab.
Net4CGD scientists in Frankfurt, Paris and London report that hyperinflammation in CGD leads to impairment of hematopoietic stem cell functions in the prestigious Journal of Allergy and Clinical Immunology. Persistent chronic inflammation in CGD is associated with hematopoietic proliferative stress leading to a decrease in the functional activity of hematopoietic stem cells. Proactive treatment of CGD patients with anti-inflammatory drugs might therefore reduce chronic sterile inflammation in CGD and in addition could have an impact on the quantity and quality of hematopoietic stem cells available for autologous gene therapy.
The article will be published in 2016.
February 25 @ 09:00 - February 26 @ 12:00
Grand Hôtel des Iles Borromées, Corso Umberto I, 67 Stresa - Italy
Net4CGD and CELL-PID are holding their first joint meeting in Stresa, Italy. The agenda for this meeting will have a strong scientific focus, including joint sessions and many opportunities for interactions between scientists from both groups and within each consortium.
Marking their first Annual Meeting, this event will give the Net4CGD consortium the opportunity to look back on the scientific progress and breakthroughs achieved over the first year of the work programme.
Contact : Dr Elodie Noël (Email address: This email address is being protected from spambots. You need JavaScript enabled to view it. )
The net4CGD network is a proud sponsor of the ESGCT and SETGyC Collaborative Congress,
Madrid from October 25 to 28, 2013.
The European Society of Gene and Cell Therapy (ESGCT) promotes basic and clinical research in gene therapy, cell therapy, and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.
The XXIInd annual ESGCT Congress with the NVGCT will take place in The Hague 23 to 26 October 2014.
For more information go to http://www.esgct.eu